Months into the current global health crisis, we’re seeing game-changing opportunities for COVID-19 test companies. So much so, it’s creating a potential $44 billion opportunity for companies, like QuestCap Inc. (STOCK:QSC).(1)
After all, demand for testing has only increased.(2)
And it’s already creating big business, as test demand outweighs supply.
One company that has already had a monster run on the news is Co-Diagnostics. Its stock ran from approximately $1.52 to approximately 30 a share.
That was a gain of approximately 1,821%
Chembio Diagnostics ran from approximately $2.50 to approximately $15.89.
That was approximately 536% growth in just months.
However, aside from those two stocks, we discovered a small stock that’s actively involved in prevention, detection, and treatment technologies to battle the pandemic.
It’s also making sizable investment in COVID-19 research.
Best of all, the company is severely undervalued at $0.23 with a market cap of just $14.9 million. Not only does it have exclusive rights to distribute the Hangzhou Laihe Biotech LYHER Novel Coronavirus IgM/IgG Antibody Combo test Kit in North America….
It also has about a 40% interest in Amino Therapeutics, which is working on a potential therapy for patients with COVID-19, which is focused on halting the replication of the virus by inhibiting its main protease.
It also just entered into a binding Letter of Intent (LOI) to acquire 100% of Las Vegas based Collection Sites, LLC to establish pop-up testing labs.
That company is QuestCap Inc. (STOCK:QSC), which has seen explosive growth of its own.
Much like Co-Diagnostics and Chembio Therapeutics, QSC has a strong history of exploding.
As you can see, the stock explodes in short bursts of time.
As it progresses in its fight against the virus, the stock could explode even higher again.
QuestCap Inc. is a social-impact investment company.
Through QuestCap’s three divisions, MedQuest, TechQuest and ClimateQuest, it seeks, secures and funds recognised sciences, technologies, and solutions that impact our global community.
It’s actively involved in prevention, detection, and treatment technologies to battle the pandemic. It’s also making sizable investment in research.
It also secured the exclusive rights to distribute the Hangzhou Laihe Biotech LYHER Novel Coronavirus IgM/IgG Antibody Combo test Kit in North America.
Amino is currently working on a potential therapy for patients with COVID-19, which is focused on halting the replication of the virus by inhibiting its main protease.
QuestCap just entered into an arms’ length agreement to acquire a 40% equity interest in Spectral Analytics, Inc.
QuestCap will also make a conditional payment of $470,000 to Spectral to fund certain clinical trials, and is conditional on IRB [Institutional Review Board] approval including the submission by Spectral of a successful in vitro study to the US Food and Drug Administration (FDA) for human trials for a combination of two FDA approved drugs for COVID-19.
Two in-vitro studies were performed at two independent pre-clinical research organizations on behalf of Spectral, to test the efficacy of the combination of two FDA approved drugs to treat COVID 19. These in-vitro studies provide Spectral full confidence that they will be able maintain safety and efficacy in administration of these drugs in COVID 19 human clinical studies.
Spectral has already received IRB approval for the clinical study and the Principal Investigator for the first Phase 1 clinical study has been initiated. Once Spectral receives approval to treat under the PIND application they will begin enrollment for the human clinical study immediately.
QuestCap Inc. also just entered into a binding Letter of Intent (LOI) to acquire 100% of Las Vegas based Collection Sites, LLC. for 20 million shares of QuestCap Inc.
Collection Sites, LLC has launched COVID-19 testing services in conjunction with Alcala Testing and Analysis Services, a CLIA registered high complexity laboratory based in San Diego, California. Alcala is a recognized expert leader in rapid COVID-19 laboratory testing.
These new testing centers will offer convenient access to antibody and antigen testing with insurance coverage options. Appointments and payments will be handled through an online portal www.testbeforeyougo.com to limit contact points at the centers.
The first phase of testing is the establishment of 11 pop-up labs, also known as ‘draw centres’, that can together administer 5,500 tests per day, with a capacity to analyze 154,000 tests a month. Additional locations are expected to open throughout Las Vegas, as well as Arizona, Texas and Indiana within the next couple of weeks.
The draw centres will be located in malls, retail centers, fitness facilities, pharmacies, stadiums, on-site in small businesses, real estate offices, law firms and schools. The second phase, expected to launch in fall 2020, appear to include mobile pop-up labs to provide access to those without transportation or unable to travel.
In addition to sizable growth potential, QuestCap Inc. (STOCK:QSC) is led by a highly experienced leadership team made up of proven leaders with extensive backgrounds and success stories from a variety of relevant industries.
CEO and Director
Doug Sommerville is a veteran leader in the North American medical, pharmaceutical and technology industries. Prior to joining QuestCap, Mr. Sommerville held the role of Head of Country for Canada for Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., the world’s leading provider of generic medicines. In this role, Mr. Sommerville was responsible for Teva’s third largest global subsidiary, with sales in excess of $1.3 billion. Douglas led all aspects of the company’s commercial, distribution, demand planning and customer operations – aligning and coordinating all company functions, production, supply chain, regulatory and global support functions. Douglas was also the Chairman of the Canadian Generic Pharmaceutical Association up until his retirement from Teva Canada in 2018.
Throughout his 25 year career, Danny Callow has overseen some of the largest investments and operations in African mining. In 2007, he constructed the Mutanda Mine in the DRC which he grew to the most profitable mine in the Corporate Group, the largest copper mine in Africa and largest cobalt mine in the world at the time. He followed this up by constructing 5 new vertical shafts at a Zambian copper mine–the most shafts ever sunk in Africa in one go and delivered these within time and budget. This investment in shafts and a new concentrator will provide this 80-year-old operation with a new low-cost lease of life for the next 30 years.
Daniyal is a seasoned professional with considerable experience providing financial and strategic advice on mergers, acquisitions and managing multiple projects for a variety of private and public companies. With experience in Central Asian and Russian markets, Daniyal plays a key role in navigating and finding new investment opportunities in frontier and emerging markets for F&M.
Chief Financial Officer
Deborah Battiston is a CPACGA, she obtained her BA in Economics from the University of Guelph and holds an ICD.D from the University of Toronto’s Rotman School of Management. Deborah has an extensive background with over 25 years of financial management, including public companies, mergers and acquisitions, tax, and financing.
Jim Rogers, Larry King, Dr. Glenn Copeland, and Mike Tyson are Advisors
Comprised of thought leaders, influencers, opinion makers and leaders within their respective fields, areas of expertise, sector and industry – they are committed to MedQuest’s mission to bring medical breakthroughs to market with power, grace and ease.
Members of the MedQuest Advisory Board will help fulfill QuestCap’s mission of searching for and investing in breakthrough sciences, technologies, research or resolutions to empower the betterment of mankind.
Dr. Joseph Sugerman
Dr. Sugerman is a board-certified otolaryngologist who manages a private practice in Los Angeles focused on the management of voice disorders. He is a past Clinical Chief at Cedars-Sinai Medical Centre. He is also a former board member of MGM Mirage, one of the world’s leading companies with significant holdings in gaming, hospitality and entertainment.
Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic diseases. He has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He is taking forward a pivotal clinical trial with antigen specific tolerization therapy for type 1 diabetes. He serves as attending neurologist at Stanford’s Lucille Packard Children’s Hospital. Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s disease. Tysabri has been taken by over 200,000 individuals with MS.
Dr. Glenn Copeland
Possessing over 45 years of experience in both orthopaedic treatment and sports medicine, Dr. Glenn Copeland is one of North America’s most prominent foot and ankle specialists. He has established unique and authoritative treatments specializing in both surgical and non-surgical procedures of the foot and ankle.
Dr. Copeland has founded and directed several highly successful medical companies including Footmaxx Inc., which converted orthopaedic evaluation of the lower extremity from moulding technology to pressure and motion mapping. Dr. Copeland was successful in opening over 1,880 clinics globally.
Larry King has conducted over 40,000 interviews over a 60-year career and is recognized worldwide as one of the best media personalities of our time. He can be seen presently hosting “Larry King Now” on Ora TV, Hulu and RT. Mr. King is best known for his TV interview and phone-in talk show, “Larry King Live” on CNN, which he hosted nightly from 1985 to 2010.
Mr. Rogers co-founded the Quantum Fund, a global-investment partnership.
During the next 10 years, the portfolio acquired 4,200%, while the S&P increased less than 50%. After retiring – at age 37, Mr. Rogers continued to manage his own portfolio and serve as a professor of finance at the Columbia University Graduate School of Business. Mr. Rogers also presciently saw the formation of the subprime mortgage crisis a year before it erupted.
Since retirement Jim Rogers embarked on a Millennium Adventure passing through 116 countries, and covering more than 245,000 kilometres, which he recounted in his book “Adventure Capitalist: The Ultimate Road Trip”.
Mike is widely recognized across Canada as a stellar health care champion and advocate. As a volunteer Vice-President of the Canadian Hemophilia Society, Mike was the national spokesperson for Canadians infected by blood tainted with Hepatitis C. His tireless efforts resulted in a landmark $2.4 billion settlement with the federal government on behalf of the victims of tainted blood. Mike was awarded the Queens Golden Jubilee Award presented by the Governor General of Canada.
As a principal with Grosso McCarthy, Mike has over 15 years of experience with the Ontario Ministry of Health and Long Term Care and over 25 years in health policy and delivery.
Mike Mancias is the Chief Human Performance Advisor to LeBron James. As Lebron’s athletic trainer and recovery specialist for over 14 years and counting, Mike is veteran in the world of Professional Basketball. Mike’s experience includes working with NFL, MLB, PGA, and top NCAA athletes. Throughout his tenure with LeBron James, Mike has quietly developed a winning human-performance blueprint that encompasses everything from preventative medicine, strength training/ rehab, nutrition, and the latest in recovery techniques that many athletes and trainers today now utilize as part of their own training programs.
Nutrition has always been a vital component of Mancias’ program for LeBrons’ performance and it continues to remain invaluable to his daily recovery program as well. It was through this focus on nutrition to performance and recovery that Mancias aided in developing the Ladder Brand and its products now available to the market.
Richard is an author, advocate and researcher on the subject of human betterment through effective and responsible investment. An internationally best selling author and highly sought after speaker, Richard has shared the stage with the likes of Presidents William Jefferson Clinton, George W. Bush, Barack Obama and Donald J. Trump. He also continues to tour alongside Secretary of State Hillary Clinton, Oprah Winfrey, Deepak Chopra, Ellen Degeneres and former First Lady, Michelle Obama.
Dr. Paulo Iglessias
General Iglessias received his medical training in the state of Rio de Janeiro, promoted through the ranks of the Brazilian army where he was Director of various Brazilian Army hospitals including Brasilia (2011-2014). In 2015, he was appointed Inspector for Health Services for the Army for the Amazon and in 2017, Vice Director of Health Services for the Brazilian Army. General Iglessias retired in 2018 and continues to be actively involved in public health issues from his home in Campo Grande, Matto Grosso do Sul, Brazil.
As both a legendary competitor and iconic figure in the world of sport, Mr. Tyson joins QuestCap’s team of global experts engaged to advise on investments in specialized industries and geographic regions.
Mr. Tyson competed as a professional boxer from 1985 to 2005. He reigned as the undisputed world heavyweight champion from 1987 to 1990 and was the first heavyweight boxer to simultaneously hold the WBA, WBC, and IBF titles, as well as the only heavyweight to successively unify them.
Mr. Tyson was known for his ferocious and intimidating boxing style as well as his provocative behavior inside and outside the ring. Nicknamed “Iron” and “Kid Dynamite” in his early career, and later known as “The Baddest Man on the Planet”, Tyson is considered one of the best heavyweights of all time. Mr. Tyson holds the third longest unified championship reign in heavyweight history with eight consecutive defenses.
One, months into the current global health crisis, it seems we’re seeing game-changing opportunities, and incredible demand for better COVID-19 testing. So much so, it’s creating a potential $10 billion opportunity for companies, like QuestCap Inc. (STOCK:QSC).
Two, QuestCap Inc. (STOCK:QSC) has a history of big returns:
Three, the company is severely undervalued at $0.23 with a market cap of just $14.9 million.
Not only does it have exclusive rights to distribute the Hangzhou Laihe Biotech LYHER Novel Coronavirus IgM/IgG Antibody Combo test Kit in North America, it also has an approx. 40% interest in Amino Therapeutics, which is working on a potential therapy for patients with COVID-19, which is focused on halting the replication of the virus by inhibiting its main protease.
Four, it also just entered into a binding Letter of Intent (LOI) to acquire 100% of Las Vegas based Collection Sites, LLC to establish pop-up testing labs.